Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β₂ -agonists in obstructive lung diseases: a population-based, observational study.

• Published in: International Journal of Clinical Practice
• Main Authors: Björnsdóttir, U S, Sigurðardóttir, S T, Jonsson, J S, Jonsson, M, Telg, G, Thuresson, M, Naya, I, Gizurarson, S
• Other Authors: Faculty of Medicine, Landspitali-The National University Hospital of Iceland, University of Iceland, Norurmýri, 101, Reykjavík, Iceland b Department of Immunology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland c Heilsugæslan Gardabaer, Gardabaer, Iceland
• Format: Article in Journal/Newspaper
• Language: English
• Published: John Wiley & Sons 2014
• Subjects: Lungnasjúkdómar; Asma; Lyfjakostnaður; Lyfjanotkun; Sjúkratryggingar; Pulmonary Disease; Chronic Obstructive/drug therapy*; Adrenal Cortex Hormones; Iceland; Health Policy; Insurance; Health; Reimbursement; Cost Control; Asthma; Drug Costs; Health Care Costs/legislation and jurisprudence; Saba
• Online Access: http://hdl.handle.net/2336/326054; https://doi.org/10.1111/ijcp.12473

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access. In 2010, the Icelandic government introduced a new cost-saving policy that limited reimbur...